Customization: | Available |
---|---|
Powder: | Yes |
Customized: | Customized |
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product Name | Cabozantinib |
CAS | 849217-68-1 |
Appearance | White crystalline powder |
MF | C32H30FN3O10 |
MW | 635.5931032 |
Purity | 99% |
Shelf Life | 2 Years |
Cabozantinib is a small molecule C-Met modulator. Cabozantinib acts as a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis.
Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL184 at low concentration(0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion.
Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL184 at low concentration(0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion.